Takeda received approval from the U.S. FDA for EOHILIA (budesonide oral suspension), the first and only approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). It will be available in 2 mg/10 mL single-dose stick packs by the end of February.   EOHILIA is a corticosteroid indicated for 12 weeks of treatment. Developed specifically for EoE, its novel formulation of budesonide confers thixotropic properties – flowing more freely when shaken and returning to a mor...